What is it about?
Our study shows that 1 out of 4 patients with type 2 diabetes are udiagnosed in this high risk population. We have validated fasting glucose and HbA1c in the screening for type 2 diabetes in a high risk population of patients with morbid obesity.
Featured Image
Why is it important?
Morbid obesity is considered a high risk population for type 2 diabetes. Our study underscores the need for continued screening for unknown diabetes which is essential for implementing risk reducing strategies in patients with morbid obesity.
Perspectives
In spite of increased viligance on the prevalence of unknown type 2 diabetes , 25 % of the patient with type 2 diabetes remains undetected. In patients with morbid obesity, fasting glucose identifies more patients than HbA1c. Increased focus on diabetes-screening should be emphazised on a societal level, i.e. general information to the population and to health care personel in general practice.
Tone Gretland Valderhaug
Akershus University Hospital
Read the Original
This page is a summary of: The usage of fasting glucose and glycated hemoglobin for the identification of unknown type 2 diabetes in high risk patients with morbid obesity, Scandinavian Journal of Clinical and Laboratory Investigation, July 2017, Taylor & Francis,
DOI: 10.1080/00365513.2017.1347958.
You can read the full text:
Contributors
The following have contributed to this page
